Olympus Corporation
Fiscal Year Ending March 2027 Second Quarter Financial Summary [IFRS] (Consolidated)
Consolidated interim results for the fiscal year ending March 2027 showed revenue of 509,593 million yen (12.2% YoY increase), adjusted operating income of 95,833 million yen (89.6% YoY increase), and net income attributable to owners of parent of 52,146 million yen, marking substantial increases. Full-year forecasts for FY2027 were left unchanged, although the lower bound of revenue guidance was raised versus the prior forecast. Capital structure changed due to acquisitions including BioProtect Ltd. By segment, both Gastrointestinal Endoscopy Solutions and Surgical Intervention businesses achieved revenue and profit growth. Continued monitoring and mitigation of FDA-related risks and strengthening of third-party risk management are ongoing.
Key Figures
- Revenue: 509,593 million yen (Year-over-Year 12.2% increase)
- Adjusted Operating Income: 95,833 million yen (Year-over-Year 89.6% increase)
- Net Income Attributable to Owners of Parent (Interim): 52,146 million yen (Year-over-Year 78.7% increase)
AI要約
Overview of Results
Olympus achieved interim consolidated revenue of 509,593 million yen for the fiscal year ending March 2027, a 12.2% increase year-over-year. Operating income increased and adjusted operating income rose substantially to 95,833 million yen. By segment, Gastrointestinal Endoscopy Solutions and Surgical Intervention both remained strong. Foreign exchange effects contributed positively. Business combinations, including the acquisition of BioProtect Ltd., affected the capital structure. Ongoing measures are being taken to address FDA-related risks.
Outlook and Capital Policy
The Company's forecast for the fiscal year ending March 2027 remains unchanged from the most recently announced guidance, while reflecting progress that raised the lower bound of revenue. Foreign exchange is expected to contribute positively, while regulatory and quality risks related to the FDA and strengthened third-party risk management remain areas of focus. Optimization of the business portfolio, including effects from the acquisition of BioProtect, is positioned as a medium- to long-term growth driver. Share buyback and dividend policies are disclosed separately; this financial summary does not indicate any new material large-scale transactions regarding treasury stock acquisition/disposition.
Comparison of Guidance and Actuals
Olympus Corporation
Company overview · Stock price · Financial data · All IR
